Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, LIPOCINE INC. reported revenue of $2M, down 82.3% year over year. Operating margin was -524.7% and net margin -487.1%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from LPCN's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $2M | -524.7% | -487.1% |
| FY2024 | $11M | -10.3% | 0.1% |
| FY2023 | $-3M | 629.0% | 573.6% |
| FY2022 | $1M | -2423.9% | -2151.7% |
| FY2021 | $16M | 19.5% | -3.9% |
How does LPCN compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.